RxDoctor Payments Data

Ayham Shneker, MD

Internal Medicine · San Antonio, TXNPI 1871557454

Payments from drug & device makers

$913,494in general payments, 2019–2025

Across 1,803 payments — averaging $506.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$814K
  • Kowa Research Institute, Inc.$59K
  • Regeneron$16K
  • AbbVie$16K
  • Lilly USA, LLC$960
  • Novo Nordisk$879
  • plus $7K from 54 others

What the payments were for

  • Travel & lodging$8757%
  • Food & beverage$11,02492%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1,084$814,475
Kowa Research Institute, Inc.28$58,502
Regeneron8$16,196
AbbVie(2 entities)149$15,546
Lilly USA, LLC59$960
Novo Nordisk83$879
Amgen(2 entities)43$784
Sanofi-aventis U.S. LLC26$429
AstraZeneca26$425
GSK26$415
Bayer19$369
Corcept Therapeutics20$355
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$349
Astellas Pharma US Inc14$283
Merck17$274
Esperion Therapeutics, Inc.14$251
Johnson & Johnson14$218
Pfizer11$188
Nestle Healthcare Nutrition Inc.9$177
Boehringer Ingelheim9$162
Amarin Pharma, Inc.10$162
Kowa Pharmaceuticals America, Inc.9$156
Takeda Pharmaceuticals U.S.A., Inc.8$153
Abbott7$146
Sumitomo Pharma America, Inc.7$140
Novartis7$122
Ironwood Pharmaceuticals, Inc7$115
Otsuka America Pharmaceutical, Inc.5$114
Shield Therapeutics Inc6$103
Insulet Corporation5$89
Genentech USA, Inc.4$65
Eisai Inc.3$64
Biohaven Pharmaceuticals, Inc.3$62
Avanir Pharmaceuticals, Inc.3$52
Evoke Pharma, Inc.2$45
Redhill Biopharma Inc.2$44
Nevro Corp.1$39
Althera Pharmaceuticals LLC2$39
Biohaven Pharmaceutical Holding Company Ltd.2$39
Ardelyx, Inc.2$37
Regeneron Healthcare Solutions, Inc.3$36
Scilex Pharmaceuticals Inc.2$33
QOL Medical, LLC2$32
Phathom Pharmaceuticals, Inc.2$32
Acerus Pharmaceuticals Corporation2$27
Nalpropion Pharmaceuticals LLC2$27
Kyowa Kirin, Inc.1$26
Dexcom, Inc.1$24
Currax Pharmaceuticals LLC2$23
Optinose US, Inc.1$21
Actelion Pharmaceuticals US, Inc.1$20
Xeris Pharmaceuticals, Inc.1$20
Mannkind Corporation1$19
Recordati_rare_diseases_inc.1$18
Exact Sciences1$18
Tolmar, Inc.1$18
Radius Health, Inc.1$18
Biogen1$15
ANI Pharmaceuticals, Inc.1$15
Antares Pharma, Inc.1$14

How this compares

$913,494 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$117,654
Medicare patients
361
Services billed
2,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide383$552,156
JardianceEmpagliflozin256$399,971
TrulicityDulaglutide140$265,970
MounjaroTirzepatide161$227,343
FarxigaDapagliflozin Propanediol157$181,712
Trelegy ElliptaFluticasone/Umeclidin/Vilanter136$165,422
EliquisApixaban91$112,142
Bydureon BciseExenatide Microspheres40$94,156
LinzessLinaclotide65$78,440
JanuviaSitagliptin Phosphate49$68,367
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog58$64,091
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$49,001
XareltoRivaroxaban38$45,893
MyrbetriqMirabegron46$45,081
ProliaDenosumab25$43,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$879$576,519397 claims
Lilly USA, LLCTrulicity, Mounjaro$960$493,313301 claims
Boehringer IngelheimJardiance, Tradjenta$162$422,415270 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$425$222,749208 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$415$194,362178 claims
PfizerEliquis$188$112,14291 claims
AbbVieLinzess, Vraylar$15,546$101,40579 claims
MerckJanuvia, Janumet Xr$274$76,99860 claims
Johnson & JohnsonXarelto$218$45,89338 claims
Astellas Pharma US IncMyrbetriq$283$45,08146 claims
AmgenProlia$784$43,65825 claims
Sumitomo Pharma America, Inc.Gemtesa$140$40,46243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →